COVID-19对血液恶性肿瘤患者SARS-CoV-2抗体应答受损
ITA-HEMA-COV项目纳入237例SARS-CoV-2 PCR阳性且至少检测一次IgG的血液恶性肿瘤患者,69%可检出IgG抗体,31%血清学阴性且在各疾病类型间分布均匀;
要点
- 血液恶性肿瘤患者COVID-19后SARS-CoV-2 IgG血清转化率仅69%。
- 血清学阴性患者在各疾病类型间分布均匀,提示治疗相关免疫功能障碍是主因。
核心结论
- 血液恶性肿瘤患者SARS-CoV-2血清转化率低,治疗介导的免疫功能障碍是主要驱动因素。
- 预期疫苗接种后血清转化率也低,建议检测该人群的血清转化效力。
研究设计与样本
- ITA-HEMA-COV项目(NCT04352556)分析237例SARS-CoV-2 PCR阳性且至少检测一次SARS-CoV-2 IgG的血液恶性肿瘤患者。
主要发现
- 总体69%(164/237)患者可检出SARS-CoV-2血清IgG抗体。
- 血清学阴性患者占31%(73/237),在髓系、淋巴系和浆细胞肿瘤患者中分布均匀。
临床怎么用
- 对血液恶性肿瘤患者,尤其接受化学免疫治疗者,应考虑检测SARS-CoV-2血清转化以评估免疫应答。
- 接种疫苗后宜评估该人群血清转化效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04-11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11-1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
引用
- Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol. 2021. PMID: 34272724. doi:10.1111/bjh.17704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。